D
David Cox
Researcher at Loughborough University
Publications - 10
Citations - 425
David Cox is an academic researcher from Loughborough University. The author has contributed to research in topics: Nitric oxide synthase & Receptor. The author has an hindex of 5, co-authored 10 publications receiving 414 citations. Previous affiliations of David Cox include AstraZeneca & Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.
Anthony Ingall,John Dixon,Andrew Bailey,Mandy E. Coombs,David Cox,Judith I. McInally,Simon F. Hunt,Nicholas Kindon,Barry Teobald,Paul Willis,R.G. Humphries,P. Leff,Jane A. Clegg,James A. Smith,Wendy Tomlinson +14 more
TL;DR: The platelet P2T receptor plays a major role in platelet aggregation, and its antagonists are predicted to have significant therapeutic potential as antithrombotic agents.
Journal ArticleDOI
2-Aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution
Stephen Connolly,Anders Åberg,Andrew S. Arvai,Haydn Beaton,David Cheshire,Anthony Ronald Cook,Sally L. Cooper,David Cox,Peter Hamley,Phil Mallinder,Ian Millichip,David J. Nicholls,Robin J. Rosenfeld,Stephen A. St-Gallay,John A. Tainer,and Alan C. Tinker,Alan V. Wallace +16 more
TL;DR: A flipping of the pyridine ring between these new inhibitors allows the piperidine to interact with different residues and confer excellent selectivity.
Patent
Novel use of phenylheteroalkylamine derivatives
TL;DR: In this article, the use of a compound of formula (I), wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.
Journal ArticleDOI
The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS).
David Cheshire,Anders Åberg,Gunilla Andersson,Glen Andrews,Haydn Beaton,Timothy Nicholas Birkinshaw,Nigel Boughton-Smith,Stephen Connolly,Tony R. Cook,Anne Cooper,Sally L. Cooper,David Cox,John Dixon,Nigel Gensmantel,Peter Hamley,Richard P. Harrison,Paul Hartopp,Helena Käck,Paul D. Leeson,Timothy Jon Luker,Antonio Mete,Ian Millichip,David J. Nicholls,Austen Pimm,Steve St-Gallay,Alan V. Wallace +25 more
TL;DR: By careful analysis of experimental X-ray ligand crystallographic protein data across several inhibitor series, a novel, potent and selective series of iNOS inhibitors exemplified by compound 8 is discovered.
Patent
Heterocyclic sulphinyl compounds
TL;DR: In this paper, novel compounds of formula I, in which Rc is a nucleophilic nitrogen, oxygen or sulphur separated from the SO group by 1, 2, 3, 4 or 5 other atoms, R1, R2, R3 and R4, which may be the same or different, are described.